IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A peptide or a salt thereof having comprising an amino acid sequence of Formula I (SEQ ID NO: 1):

 X_1 [Lys X_2 X_3 Phe Gln]_m Arg Gln Ile [Lys X_4 Pro Phe Gln]_n X in which wherein X_1 is absent or is an acetyl group;

 X_2 and X_4 are independently selected from the group consisting of Ileu and Leu;

X₃ is selected from the group consisting of Pro and Trp;

X is a peptidic moiety of a length selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8 amino acids and wherein X comprises containing at least one basic amino acid and wherein X which is amidated at the C-terminus;

m is an integer selected from the group consisting of 0 and 1; n is an integer selected from the group consisting of 1 and 2; as well as salt thereof.

Claim 2 (Currently Amended): A <u>The peptide according to of claim 1</u>, wherein X is a peptidic moiety of a length selected from the group consisting of 5, 6, 7 and 8 amino acids and wherein X containing comprises at least one basic amino acid.

Claim 3 (Currently Amended): A <u>The</u> peptide according to any of the preceding elaims claim 1, wherein X comprises at least one basic amino acid selected from the group consisting of Lys and Arg.

Claim 4 (Currently Amended): A <u>The</u> peptide according to <u>claim 1</u> any of the <u>preceding claims</u>, wherein X is the <u>following</u> peptidic moiety (SEQ ID NO: 2):

Asn X₅ X₆ Met X₇ Trp X₈ X₉-NH₂ wherein

 X_5 , X_6 , X_7 , X_8 and X_9 are independently selected from the group consisting of Arg and Lys.

Claim 5 (Currently Amended): A <u>The</u> peptide according to any of the preceding elaims claim 1 wherein X is of SEQ ID NO: 10.

Claim 6 (Currently Amended): A The peptide according to claim 1, wherein m is 0 and n is 1.

Claim 7 (Currently Amended): A The peptide according to claim 1 wherein X_1 is acetyl.

Claim 8 (Currently Amended): A The peptide according to claim 1, wherein m is 0 and n is 2.

Claim 9 (Currently Amended): A The peptide according to claim 1, wherein m is 1 and n is 1.

Claim 10 (Currently Amended): A <u>The peptide according to claim 1 any claims from 1 to 9</u> selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO: 8.

Claim 11 (Canceled).

Claim 12 (Original): A pharmaceutical composition comprising a the peptide according to any one of claims 1 to 10 of claim 1 and a pharmaceutically acceptable excipient, diluent, or carrier, or combination thereof.

Claim 13 (Currently Amended): A method of treating at least one of Alzheimer's disease, Dementia pugilistica, Hereditary Cerebral Haemorrage with amyloidosis of the Dutch type (HCHWA-D), head trauma, and vascular dementia with amyloid angiopathy, in a subject in need thereof, comprising

administering Use of a peptide, or a salt thereof, according to of Formula (II) (SEQ ID NO: 3):

X₁ [Lys X₂ X₃ Phe Gln]_m Arg Gln Ile [Lys X₄ X₅ Phe Gln]_n X to the subject in need thereof in an amount sufficient to treat one of Alzheimer's disease, Dementia pugilistica,

Hereditary Cerebral Haemorrage with amyloidosis of the Dutch type (HCHWA-D), head trauma, and vascular dementia with amyloid angiopathy, wherein in which

 X_1 is absent or is an acetyl group;

 X_2 and X_4 are independently selected from the group consisting of Ile and Leu;

X₃ and X₅ are independently selected from is the group consisting of Pro and Trp;

X is a peptidic moiety of a length selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8 amino acids and containing wherein X comprises at least one basic amino acid and which wherein X is amidated at the C-terminus;

m is an integer selected from the group consisting of 0 and 1;

n is an integer selected from the group consisting of 1 and 2;

as well as salts thereof for the preparation of a medicament for the treatment or prevention of a disease or condition selected from Alzheimer's disease, Dementia pugilistica

(including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.

Claim 14 (Currently Amended): Use according to The method of claim 13 wherein X_5 is Trp.

Claim 15 (Currently Amended): Use according to The method of claim 13 wherein the peptide according to of Formula (II) is of SEQ ID: 1.

Claim 16 (Currently Amended): Use according to The method of claim 13 wherein X₄ is Ile.

Claim 17 (Currently Amended): Use according to The method of claim 13 wherein X is a peptidic moiety of a length selected from the group consisting of 5, 6, 7 and 8 amino acids and wherein X comprises containing at least one basic amino acid.

Claim 18 (Currently Amended): Use according to The method of claim 13 any claims from 13 to 17 wherein X comprises at least one basic amino acid selected from the group consisting of Lys and Arg.

Claim 19 (Currently Amended): Use according to any claims from 13 to 18 The method of claim 13 wherein X is the peptidic moiety (SEQ ID NO: 2) as defined above; or a derivative or analog thereof.

Claim 20 (Currently Amended): Use according to any claims from 13 to 19 The method of claim 13 wherein X is of SEQ ID NO: 10.

Claim 21 (Currently Amended): Use according to The method of claim 13, wherein m is 0 and n is 1.

Claim 22 (Currently Amended): Use according to any of the preceding claims from 13 to 21 The method of claim 13 wherein X₅ is Trp, X is the peptidic moiety of SEQ ID NO: 2 as defined above, m is 0 and n is 1.

Claim 23 (Currently Amended): Use according to The method of claim 13, wherein m is 1 and n is 1.

Claim 24 (Currently Amended): Use according to any claims from 13 to 23 The method of claim 13 wherein X the peptide is of SEQ ID NO: 4.

Claim 25 (Currently Amended): Use according to any claims from 13 to 24 The method of claim 13 wherein the peptide X is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9[[)]].

Claim 26 (Currently Amended): Use according to any of the preceding claims from 13 to 25 The method of claim 13, wherein the disease is Alzheimer's disease.